June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
REAL-LIFE EFFICACY WITH ILUVIEN® (FLUOCINOLONE ACETONIDE [FAC]) IN DIABETIC MACULAR EDEMA (DME) PATIENTS IN 4 PORTUGUESE OPTHALMOLOGY UNITS
Author Affiliations & Notes
  • Angelina Meireles
    Ophthalmology, Centro Hospitalar Porto-HSA, Porto, Portugal
    Instituto de Ciências Biomédicas Abel Salaza, Porto, Portugal
  • Bernardete Pessoa
    Ophthalmology, Centro Hospitalar Porto-HSA, Porto, Portugal
  • João Coelho
    Ophthalmology, Centro Hospitalar Porto-HSA, Porto, Portugal
  • Carla Teixeira
    Ophthalmology, Hospital Pedro Hispano, Porto, Portugal
  • Manuel Alberto Falcão
    Ophthalmology, Centro Hospitalar S. João, EPE, Porto, Portugal
    Faculty of Medicine of the University of Porto, Porto, Portugal
  • Rita Gonçalves
    Ophthalmology, Hospital Pedro Hispano, Porto, Portugal
  • Marta Ines Silva
    Ophthalmology, Centro Hospitalar S. João, EPE, Porto, Portugal
  • João Paulo Castro e Sousa
    Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal
  • Footnotes
    Commercial Relationships   Angelina Meireles, None; Bernardete Pessoa, None; João Coelho, None; Carla Teixeira, None; Manuel Alberto Falcão, None; Rita Gonçalves, None; Marta Ines Silva, None; João Paulo Castro e Sousa, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 958. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Angelina Meireles, Bernardete Pessoa, João Coelho, Carla Teixeira, Manuel Alberto Falcão, Rita Gonçalves, Marta Ines Silva, João Paulo Castro e Sousa; REAL-LIFE EFFICACY WITH ILUVIEN® (FLUOCINOLONE ACETONIDE [FAC]) IN DIABETIC MACULAR EDEMA (DME) PATIENTS IN 4 PORTUGUESE OPTHALMOLOGY UNITS
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):958.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : ILUVIEN® implant provides a sustained, controlled microdose (0.2 μg per day) of FAc for up to 3 years. The aim of this retrospective, multi-center analysis was to investigate the visual and anatomical outcomes of eyes with DME that were treated with ILUVIEN® at 4 ophthalmic units in Portugal.

Methods : A retrospective, case series involving 81 eyes treated with a single intravitreal FAc implant following an insufficient response to prior DME treatment. Eyes were followed-up for 6.6±4.8 months. Outcomes included mean changes in best-corrected visual acuity (BCVA; ETDRS letters), and central foveal thickness (CFT). Other efficacy measures included the percentage of patients having a CFT reduction ≥20% and having a ≥10 and ≥15 letter gain in BCVA. Moreover, the percentage of patients achieving driving vision (≥70 letters) was also assessed.

Results : At baseline, the ratio of pseudophakic-to-phakic eyes was 64-to-17, respectively. All eyes had previously been injected with intravitreal anti-VEGF (mean, 4.6±4.25; range, 0 to 16) and/or steroid (mean, 2.3±1.8; range, 0 to 7). At the last observation point, following the FAc implant, mean BCVA had increased by +8.7±15.4 ETDRS letters (range, -30 to +58 letters) with 31% eyes achieving driving vision (≥70 letters). Mean CFT decreased by 202±179.7 µm (range, -201 to 334 µm). Moreover, 71.6% of patients experienced a reduction in CFT of ≥20% and in 50.7% and 38.3% of eyes, BCVA improved by ≥10 and ≥15 letters, respectively.

Conclusions : In these real-world ILUVIEN® cases, patients experienced concurrent improvements in visual acuity and CFT 6.6 months after therapy was initiated. These responses were evident in patients that had been heavily injected with anti-VEGF and short-acting steroids prior to receiving an ILUVIEN® implant.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×